UNITY Biotechnology, Inc. to Announce First Quarter 2018 Financial Results

SAN FRANCISCO, May 29, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ: UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, plans to report results for the first quarter ended March 31, 2018, on Thursday, June 7, 2018, after NASDAQ market close. 

UNITY will not conduct a conference call in conjunction with the financial results press release.

About UNITY Biotechnology UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter.

Investors
UNITY Biotechnology, Inc.
Bob Goeltz
Chief Financial Officer
1-650-525-4980
[email protected]

Media
Canale Communications
Jason Spark
1-619-849-6005
[email protected]

You May Also Be Interested In

• Is the global equity rally broadening? UBS weighs in
• Ross Stores, Inc. (ROST) PT Raised to $240 at Bernstein SocGen Group
• Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions